MMV and Anacor Collaborate to Develop Antimalarial Drugs

27 April 2010 (Last Updated April 27th, 2010 18:30)

Medicines for Malaria Venture (MMV) and Anacor Pharmaceuticals have entered into a research collaboration to develop new therapeutics to treat malaria. Anacor will lead the research effort and MMV will extend its expertise in the field as well as provide financial support. Bot

Medicines for Malaria Venture (MMV) and Anacor Pharmaceuticals have entered into a research collaboration to develop new therapeutics to treat malaria.

Anacor will lead the research effort and MMV will extend its expertise in the field as well as provide financial support.

Both partners will explore Anacor's boron chemistry platform to develop new drugs for malaria treatment.

Anacor focuses on discovering, developing and commercialising drugs based on its boron chemistry platform, while MMV is a not-for-profit organisation that aims to reduce the malaria burden with the discovery, development and delivery of antimalarial drugs.

Annually, Malaria kills over 850,000 people with the majority being children under five and pregnant women.